West Pharmaceutical Services, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a WST research report →
Range $390 – $475
Price Chart
About the company
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products.
- CEO
- Michel Lagarde
- IPO
- 1980
- Employees
- 10,800
- HQ
- Exton, PA, US
Get TickerSpark's AI analysis on WST
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $27.19B
- P/E
- 45.52
- Fwd P/E
- 41.13
- PEG
- 1.42
- P/S
- 8.37
- P/B
- 9.69
- EV/EBITDA
- 29.26
- Div Yield
- 0.23%
- Gross Margin
- 37.59%
- Op Margin
- 22.97%
- Net Margin
- 18.81%
- ROE
- 21.08%
- ROIC
- 17.89%
Latest fiscal year · YoY change
- Revenue
- $3.07B+6.3%
- Gross Profit
- $1.10B+10.1%
- Op Income
- $617.40M
- Net Income
- $493.70M+0.2%
- EPS
- $6.83+1.2%
- OCF Growth
- +15.5%
- FCF Growth
- +69.6%
- 52W High
- $438.27
- 52W Low
- $223.83
- 50D MA
- $385.65
- 200D MA
- $324.87
- Beta
- 1.14
- RSI (14)
- 43
- Avg Volume
- 617.30K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
West Pharmaceutical Services delivered a strong Q3 with double-digit organic growth, meaningful margin expansion, and raised full-year revenue and EPS guidance.· October 29, 2026
- Q3 revenue was $874 million, up 8.7% reported and 11.9% organically; adjusted EPS was $2.66, up 36% year over year.
- Gross margin improved to 39.7%, up 310 basis points, and adjusted operating margin reached 25.3%, up 420 basis points.
- Proprietary Products was the main driver: 16.6% organic growth, with HVP Components up 20% and HVP Delivery Devices up 26% excluding SmartDose 3.5.
- West Vantage declined 6.6% organically, but management said it was slightly better than expected as higher-value program ramps offset legacy roll-offs.
- The company raised full-year 2026 guidance for revenue, organic growth, and EPS, and expects Q4 revenue of $820 million-$830 million.
- Management highlighted continued strength in GLP-1, biologics, Annex 1-driven HVP upgrades, and new capacity investments, while noting FX and SmartDose roll-off will create headwinds.
West reported Q3 revenue of $874 million, up 8.7% reported and 11.9% organically. Adjusted EPS was $2.66, up 36% year over year and $0.47 above the midpoint of prior guidance. Total company gross margin was 39.7%, up 310 basis points year over year, and adjusted operating margin was 25.3%, up 420 basis points. Proprietary Products grew 16.6% organically, including HVP Components at $467 million and up 20% organically, HVP Delivery Devices at $99 million and up 26% organically excluding SmartDose 3.5, and Standard Products up 3% organically. West Vantage revenue was $146 million and down 6.6% organically. For the first nine months, free cash flow was $278 million and capital expenditures were $125 million; full-year CapEx is now expected to be $215 million-$220 million. Full-year 2026 revenue guidance was raised to $3.41 billion-$3.42 billion, implying 11.3%-11.6% organic growth, and adjusted EPS guidance was raised to $9.38-$9.48. Q4 revenue guidance is $820 million-$830 million. Management expects full-year operating margins to expand almost 300 basis points, with FX contributing a 120 basis point benefit and SmartDose 3.5 reducing reported growth by 160 basis points; they also said SmartDose 3.5 will create a roughly 290 basis point headwind to reported growth next year.
Michel Lagarde framed the quarter as evidence that West’s core business is strong and that the company can build on its technical and regulatory expertise. He emphasized two priorities: deepening strategic customer relationships and strengthening continuous improvement through automation, digitization, and better execution across the footprint. His tone was upbeat and confident, with repeated comments that West has strong secular tailwinds, a firm leadership position, and room to compound growth further.
Bob McMahon focused on the financial upside from mix, pricing, and leverage. He said Q3 outperformance was driven by proprietary growth, positive mix into HVP Components, and price contribution of just over 4 percentage points, with gross margin benefits from plant performance and pass-through recovery. He also noted nine-month free cash flow of $278 million, CapEx of $125 million, and a full-year CapEx outlook of $215 million-$220 million, while highlighting balance sheet flexibility from a renewed $750 million revolver, $47 million in dividends paid year to date, 2.4 million shares repurchased for $685 million, and an 18% dividend increase.
Analysts pressed on Asia growth, GLP-1 sustainability, HVP Delivery Devices strength, margins, CapEx, and West Vantage. Management said Asia Pacific’s 42% growth was driven mainly by India and China and by GLP-1 introductions, while GLP-1 remained a durable long-term driver with no one-time boost in the quarter and potential from Medicare Bridge, ex-U.S. generics, and next-generation molecules. On HVP Delivery Devices, they said growth was broad-based rather than tied to one launch, but Q4 would not likely repeat Q3’s level; on margins, they said they remain optimistic about further expansion. On CapEx, they reiterated comfort with the 6%-8% of revenue range and said new HVP finishing capacity should come online in 18-24 months. On West Vantage, they said the strategy remains to shift toward higher-value-added drug handling while rolling off legacy programs.
The quarter showed broad-based operating strength, with proprietary products growing strongly, HVP and GLP-1 still accelerating, and margins expanding faster than planned. Management sounded confident that regulatory tailwinds, customer adoption, and additional HVP capacity investments can support multi-year growth.
West Vantage remains a drag as legacy roll-offs offset new program ramps, and management expects that muted effect to continue this year and next. SmartDose 3.5 is gone going forward, which management said will create a reported-growth headwind next year, and Q4 growth in HVP Delivery Devices is expected to slow from Q3’s unusually strong pace.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.2%
- Shares Outstanding
- 69.66M
- Float Shares
- 69.14M
of shares held by institutions
860 13F filers
Congressional trading
Senate and House stock disclosures for WST, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Lisa C. McClainHouse · MI09 | Buy | Jun 17, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Jul 22, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Sell | Apr 8, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Buy | Feb 25, 25 | Filing → |
| Jared MoskowitzHouse · FL23 | Sell | Feb 13, 25 | Filing → |
| Jared MoskowitzHouse · FL23 | Sell | Nov 8, 24 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 9, 24 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 9, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 9, 24 | Filing → |
| Jared MoskowitzHouse · FL23 | Buy | Dec 28, 23 | Filing → |
| Jared MoskowitzHouse · FL23 | Buy | Jul 14, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Mar 20, 24 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Feb 13, 24 | Filing → |
| Jared MoskowitzHouse · FL23 | Buy | Dec 28, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 9.54M | ▼ 165.78K |
| Blackrock, Inc. | 6.70M | ▲ 50.71K |
| Fmr LLC | 5.99M | ▲ 2.41M |
| Vanguard Capital Management LLC | 4.61M | ▼ 7.31K |
| Vanguard Portfolio Management LLC | 4.13M | ▲ 114.37K |
| State Street Corp | 3.33M | ▼ 19.26K |
| Artisan Partners Limited Partnership | 2.01M | ▼ 403.99K |
| Geode Capital Management, LLC | 1.94M | ▲ 33.26K |
| Bank Of New York Mellon Corp | 1.74M | ▼ 304.97K |
| Morgan Stanley | 1.57M | ▼ 8.12K |
| T. Rowe Price Investment Management, Inc. | 1.56M | ▼ 247.86K |
| Invesco Ltd. | 1.19M | ▲ 178.34K |
Held by 1,722 ETFs
Biggest fund positions in WST by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | HAUGEN JANET BRUTSCHEA | other | 44 |
| Sep 15, 26 | Favorite Annette F | other | 2,524 |
| Sep 14, 26 | Favorite Annette F | other | 2,500 |
| Sep 11, 26 | Favorite Annette F | sell | 2,500 |
| Sep 14, 26 | Favorite Annette F | sell | 2,500 |
| Sep 15, 26 | Favorite Annette F | sell | 2,524 |
| Sep 11, 26 | Favorite Annette F | other | 2,500 |
| Sep 14, 26 | Favorite Annette F | other | 2,500 |
| Sep 15, 26 | Favorite Annette F | other | 2,524 |
| Sep 8, 26 | Favorite Annette F | other | 2,818 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our WST coverage
Recent articles, reports, and earnings notes.
No research on WST yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate WST report →My Top Dividend Growth Picks In Each GICS Sector (November 2026)
seekingalpha.com · Nov 20
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
zacks.com · Nov 19
West Pharmaceutical Services, Inc. (WST) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 18
Artisan Global Discovery Fund Q3 2026 Portfolio Activity
seekingalpha.com · Nov 18
West Pharmaceutical Services, Inc. $WST Position Increased by Eurizon Capital SGR S.p.A.
defenseworld.net · Nov 16
Candriam S.C.A. Purchases 3,140 Shares of West Pharmaceutical Services, Inc. $WST
defenseworld.net · Nov 9
West Pharmaceutical Services (WST) is a Great Momentum Stock: Should You Buy?
zacks.com · Nov 5
West to Participate in Upcoming Investor Conference
prnewswire.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.